Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
CNS Spectrums|July 4, 2006
Defining and diagnosing involuntary emotional expression disorderJeffrey L Cummings, David B Arciniegas, Benjamin R Brooks, et al.
Neurology|July 1, 1995
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Bioelectromagnetics|April 16, 2003
No influence of magnetic fields on cell cycle progression using conditions relevant for patients during MRIIlka B Schiffer, Wolfgang G Schreiber, Robert Graf, et al.
CNS Spectrums|June 21, 2005
The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meetingDavid B Arciniegas, Edward C Lauterbach, Karen E Anderson, et al.
Journal of Sex Research|November 30, 2018
An Exploratory Study on the Central Nervous Correlates of Sexual Excitation and Sexual InhibitionK Unterhorst, H Gerwinn, A Pohl, et al.
Molecular Carcinogenesis|February 24, 2006
Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor modelCarolin K Hausherr, Ilka B Schiffer, Susanne Gebhard, et al.
British Journal of Cancer|January 11, 2007
Role of the progesterone receptor for paclitaxel resistance in primary breast cancerM Schmidt, E Bremer, D Hasenclever, et al.
Anticancer Research|May 17, 2002
Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude miceJ Hast, I B Schiffer, B Neugebauer, et al.
Translational Psychiatry|May 17, 2017
Gray matter anomalies in pedophiles with and without a history of child sexual offendingB Schiffer, T Amelung, A Pohl, et al.
Neurology|April 1, 1998
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupK P Johnson, B R Brooks, J A Cohen, et al.
Pageof 8